Author(s): Symonne Martin, MD, Destiny Anamege, MD, MBA, Emanuel Narcis Husu, MD
Originally published: November 10, 2011 Last updated: April 9, 2026
Jump to:

Disease/Disorder

Definition

Inflammatory arthritides encompass a group of joint diseases characterized by stiffness, pain, and progressive damage to synovial joints and related structures. They can be monoarticular, oligoarticular, or polyarticular and may follow an acute or chronic course. Four recognized groups include

  • Autoimmune Inflammatory Arthritis (e.g., rheumatoid arthritis, systemic lupus erythematosus)
  • Crystal-induced inflammatory arthritis (e.g., gout, pseudogout, BCP)
  • Seronegative spondyloarthropathies (e.g., ankylosing spondylitis, psoriatic arthritis)
  • Infectious or septic arthritis (e.g., gonorrhea, tuberculosis, osteomyelitis)

Etiology

The etiology of inflammatory arthritides is multifactorial and largely unknown. Inflammation and autoimmunity are considered key factors. Rheumatoid arthritis (RA) is associated with the HLA subtype DR41, as well as increased expression of IL-6 and TNF-α. Psoriatic arthritis (PsA) is associated with both IL-23 and IL-17A.2 Systemic lupus erythematosus (SLE) is associated with MCP-1 polymorphism.3 Bacteria, fungi, and viruses can cause infectious inflammatory arthropathies, leading to potentially serious complications such as septic arthritis.4

Epidemiology including risk factors and primary prevention

Inflammatory arthritides affect all age groups, although certain populations are more susceptible. The incidence of inflammatory arthritis ranges from 115 to 271 per 100,000 adults, while the incidence of undifferentiated inflammatory arthritis ranges from 41 to 149 per 100,000 adults. Of those with undifferentiated arthritis, up to 54% will eventually develop rheumatoid arthritis.5 Globally, the incidence rate of RA has increased to 13.5 per 100,000 adults; however, the mortality rate over the past three decades has decreased to 0.06 per 100,000. Smoking remains a significant modifiable risk factor for RA-related mortality.6 Peak incidence of RA occurs around 60 years of age, with a lifetime risk amongst women of 3.6% versus 1.7% amongst men, or a 2-3:1 ratio.7 In systemic lupus erythematosus, sex differences vary by age, affecting men and women equally in childhood versus disproportionately affecting women 9:1 in adulthood.8 The incidence of PsA is 3.6 –7.2 per 100,000, with a mean age at diagnosis of approximately 50 years and a rising prevalence since 2020.9,10 Gout is the most common acute inflammatory arthritis, with an incidence of 4 per 1,000 adults in males and 1.4 per 1,000 in females.11 Infectious arthritis incidence remains low at 4 per 100,000; however, this increases to 180-240 per 100,000 among patients with concurrent RA.12

Pathophysiology

Inflammatory arthritides begin with an inflammatory response that disrupts joint structure and function. An immune response to external or self-antigens leads to an influx of inflammatory cells such as neutrophils, lymphocytes, and macrophages. Activated T-lymphocytes stimulate monocytes to produce pro-inflammatory cytokines. Neutrophils release proteases and elastases that degrade joint and periarticular tissues, causing synovitis and progressive cartilaginous and osseous damage.13 RA can be triggered at mucosal sites, particularly the lungs and GI tract, years before joint symptoms appear. Environmental exposures, such as cigarette smoke, activate peptidyl arginine deiminase enzymes that convert arginine to citrulline. In susceptible individuals, this triggers autoantibody production when presented by HLA-DR molecules.14 Monosodium urate crystals accumulate in gout, whereas calcium pyrophosphate and cholesterol crystals precipitate inflammatory responses in pseudogout.15 Individuals who are HLA-B27-positive are more susceptible to developing seronegative spondyloarthropathies.16 Infectious arthritis is typically due to bacterial joint invasion via hematogenous seeding (most commonly), direct inoculation, or contiguous spread from a nearby focus of infection.17

Disease progression including natural history, disease phases or stages, disease trajectory (clinical features and presentation over time)

Early RA typically presents with bilateral joint swelling and pain accompanied by morning stiffness that improves with activity. In contrast, seronegative spondyloarthropathies often present asymmetrically and with higher disease burden at diagnosis.18 Distal interphalangeal disease suggests PsA. Back pain suggests ankylosing spondylitis (AS), although sacroiliitis may not be evident early in the disease course. The spine progressively stiffens with possible ankylosis or joint fusion that can involve the chest wall.19 As the fusion progresses, the pain can improve. Enthesitis, or inflammation at tendon insertion points, is common among seronegative spondyloarthropathies.20 Crystal-induced arthritides, including gout and pseudogout, will typically have a sudden, unilateral onset involving the first metatarsophalangeal joint or ankle.15 Viral-related arthritis often presents with myalgias and fever and is usually self-limiting.

Specific secondary or associated conditions and complications

Cutaneous and nail findings, including psoriatic plaques, nail pitting, and onycholysis (nail separation from the nail bed) are characteristic of PsA. SLE is associated with rashes, oral ulcers, and renal involvement. RA is associated with cardiopulmonary disease, vasculitis, renal impairment, increased lymphoma risk, and cervical spine involvement.19 Cardiovascular disease remains the leading cause of death in patients with RA, with a twofold increased risk of myocardial infarction compared to the general population.21 In AS, costovertebral and sternocostal involvement can lead to restrictive lung disease. Seronegative arthritides are also seen in up to 39% of patients with inflammatory bowel disease.22 Treatment-related complications like infection, demyelinating disorders, and malignancy should be routinely screened for in patients receiving immunomodulatory therapy.20

Essentials of Assessment

History

Joint pain is the most common presenting symptom of inflammatory arthritides. To differentiate between disease types, information about symptom onset, location, symmetry, presence of stiffness, edema, or types of pain should be obtained on the initial encounter. An acute onset may suggest an infectious etiology or crystalline arthropathy, while a subacute or insidious onset is more typical of autoimmune inflammatory arthropathies.5 Symptom duration and aggravating or alleviating factors can also differentiate acute inflammatory from non-inflammatory arthritis. Constitutional symptoms, including fatigue, weight loss, or fever, suggest systemic disease. A history of previously damaged joints and lower extremities, such as the knees, is common in bacterial infectious arthritis.5

Physical Examination

Examine all joints, peripheral and axial, for pain, effusion, synovitis, deformities, range of motion (ROM), and strength. Note the location and number of joints affected. The first metatarsophalangeal joint is affected in approximately 50% of patients with gout at initial presentation and in up to 90% of gout cases over time.5 The knees, wrists, and second and third metacarpophalangeal joints of the hands are usually associated with pseudogout.5 Small joints of the upper and lower extremities such as the proximal interphalangeal (PIP), metacarpophalangeal (MCP), or metatarsophalangeal (MTP) joints are commonly affected in RA, but the spine (except the C1-C2 joints) and distal interphalangeal joints in the hands are usually spared in RA.5,13 RA also has symmetrical, polyarticular involvement including extra-articular manifestations of vasculitis, nodules, or ophthalmic involvement.19 Though pauciarticular, AS commonly affects the lumbar spine and sacroiliac joints, and the cervical spine can be involved with possible fractures or kyphosis in addition to ophthalmic or gastrointestinal involvement, dactylitis, or enthesitis.16 Nail lesions or iritis suggest PsA. Acute monoarticular arthritis is likely infectious or crystal-induced. Proximal muscle weakness and muscle pain suggest polymyositis, though neuromuscular disease cannot be excluded. Dry eyes, parotid enlargement, or lymphadenopathy are observed in Sjögren syndrome. Oral ulcers are seen in Behçet disease. Cognitive deficits can occur in SLE. Inflammatory arthritis secondary to viruses such as hepatitis B, hepatitis C, and parvovirus B19 have a polyarticular pattern and clinical presentation similar to RA.

Functional assessment

The physiatrist’s role includes assessing function, structure, activities, participation, and quality of life (QOL). The Medical Outcome Survey Short Form 36 assesses QOL.23 Functional assessment tools that evaluate mobility, self-care, and pain include the Health Assessment Questionnaire (HAQ), “Timed Up and Go” test, 6-minute walk test, Bath Ankylosing Spondylitis Functional Index, Psoriatic Arthritis Screening and Evaluation, and Arthritis Impact Measurement Scales.24,25 It is also important that physiatrists are familiar with the five preferred RA disease activity measures selected by the American College of Rheumatology for regular clinical use: the CDAI, DAS28-ESR/CRP, PAS-II, RAPID3, and SDAI.26

Laboratory studies

CBC, erythrocyte sedimentation rate (ESR), rheumatoid factor, and metabolic panels aid in the diagnosis of inflammatory arthritides. C-reactive protein, serum complement, and ESR are useful for disease monitoring but require clinical correlation, as these inflammatory markers are elevated in many inflammatory arthropathies.5 Hyperuricemia is frequently seen in patients with gout, but during an acute attack of gout, serum uric acid levels may be falsely low.5 Patients with pseudogout secondary to underlying metabolic diseases, such as hypercalcemia, hyperparathyroidism, hypomagnesemia, and hemochromatosis, may have laboratory studies associated with the underlying condition.1 Specific autoantibodies correlate with specific diseases, i.e., anti-cyclic citrullinated peptide antibodies have been seen to be positive in up to 70% of patients with RA, while anti-double-stranded DNA/Smith antibodies are found in SLE.12,27 Synovial fluid should be sent for gram stain, culture, cell count, and crystal analysis if crystal-induced or septic arthritis is suspected.

Imaging

A normal radiograph does not exclude arthritis. In early RA, imaging may show periarticular osteoporosis, with marginal bony erosions appearing later. SLE can develop a non-erosive arthropathy, which distinguishes it from RA. Punched-out lesions adjacent to bone suggest gout, while fibrocartilage calcinosis indicates pseudogout. It is advisable to pursue cervical spine imaging in patients with RA who develop neurological symptoms, gait instability, or chronic neck pain.16

Magnetic resonance imaging (MRI) has gained attention for non-invasive early detection of synovial, soft tissue, or bone changes as well as axial inflammatory disease.16,28 Intravenous gadolinium contrast optimizes synovitis assessment. Bone marrow edema (BME), bone erosion, or fat infiltration precede sacroiliitis visible on plain radiograph, aiding in earlier AS diagnosis. BME on MRI is associated with RA disease progression.29

Ultrasound (US) offers a low-cost, portable alternative. US detects extra-articular changes including tenosynovitis, bursitis, or enthesopathies, differentiating RA from other seronegative spondyloarthropathies. It has been shown to detect subclinical synovitis in RA, which in turn reduces the time to diagnosis and the number of clinical visits prior to final diagnosis.30,31

Nuclear Medicine joint scans are not routinely utilized in diagnosing inflammatory arthritides due to their high sensitivity but very poor specificity. Nevertheless, they can be used to evaluate the presence or absence of inflammation and prosthetic joint infections.5

Supplemental assessment tools

Arthroscopy allows direct visualization of articular surfaces. Synovial biopsy to differentiate synovitis phenotypes may help diagnose ill-defined arthritis or characterize treatment-refractory arthritis.32

Early prediction of outcomes

Morbidity and mortality rates among patients with inflammatory arthritides are inversely related to educational level.33 Positive RF and elevated acute-phase reactants in severe RA suggest poor outcomes. ESR, baseline joint erosions, and HLA-DR1 alleles can predict joint damage, while five-year disability can correlate with HAQ scores and joint counts.34

Environmental

Environmental assessment should include evaluation of the home, workplace, and transportation to identify necessary accommodations. Given the high rates of work disability, at-risk patients should be engaged in vocational rehabilitation programs early.35

Social roles and social support system

The ability to function at work, within the family, and in the community is often disrupted. Comorbid conditions, including depression and anxiety, can increase a patient’s pain burden, so patients should be periodically screened and referred for psychosocial support as needed.

Rehabilitation Management and Treatments

Available or current treatment guidelines

The treatment for inflammatory arthritides is largely guided by well-established approaches for rheumatoid arthritis and spondyloarthritis. The goals of initial therapy are suppression of inflammation, prevention of further joint damage, and preservation of function using combination therapy. Conventional systemic disease-modifying antirheumatic drugs (csDMARDs) such as methotrexate, sulfasalazine, and hydroxychloroquine, along with anti-inflammatory therapies, including systemic glucocorticoids and nonsteroidal anti-inflammatory drugs (NSAIDs), effectively achieve remission and slow radiographic disease progression more than monotherapy alone in RA.36 Optimal outcomes are achieved by starting combination therapy within 3 months of presentation to control disease activity, delay progression, or achieve remission.36 NSAIDs provide symptomatic relief; however, their use is limited due to adverse gastrointestinal, renal, and cardiovascular effects. In PsA, NSAIDs should be used as monotherapy only in patients with mild symptoms, and systemic glucocorticoids are not recommended.37

Biologic disease-modifying antirheumatic drugs (bDMARDs) are an expensive and powerful class of medications used for the treatment of inflammatory arthritides following inadequate response to initial combination therapy for at least three months. The classes of bDMARDs available for RA are tumor necrosis factor-alpha inhibitors, CD-20 depleting antibodies, interleukin-6 inhibitors, T-cell co-stimulation inhibitors, and IL-1 inhibitors.29 These medications increase an individual’s risk for infections and are contraindicated with active infections or current malignancy.36 Clinical trials in early RA comparing csDMARDs and glucocorticoids with the combination of csDMARDs and bDMARDs have not demonstrated significant differences in long-term outcomes.38 Janus kinase inhibitors, also known as targeted synthetic DMARDs (tsDMARDs), are establishing a role in the management of rheumatoid arthritis and other inflammatory arthritic conditions, particularly in patients without cardiovascular risk factors, following csDMARD failure, or when cs/bDMARDs are contraindicated.37,39 Deucravacitinib, a selective JAK inhibitor of TYK2-protein kinase, has shown superior efficacy compared to placebo in adults with active PsA who were not previously treated with a bDMARD.40 A new experimental therapy, Rosnilimab, is a selective pathogenic T-cell depleting agent that has shown promising safety, tolerability, and efficacy in the treatment of moderate-to-severe RA.41 Anti-hyperuricemic agents, such as allopurinol, are used for crystal-induced arthritides.

Exercise considerations

Rehabilitation strategies include orthoses, joint protection techniques, energy conservation strategies, strengthening, stretching, and modalities. Activity pacing reduces joint inflammation and fatigue. Muscle strengthening with moderate-impact aerobic exercise decreases disease activity, depression, and femoral bone loss while improving sleep and QOL in patients with RA. Similar evidence supports an anti-inflammatory role of physical activity in juvenile idiopathic arthritis, inflammatory myositis, SLE, and AS.42 Exercise combined with pharmacologic treatment improves spinal mobility, ADL function, and QOL in AS.43

Exercise prescriptions should target affected joints to maintain strength, ROM, bone mineralization, and increase endurance.44 Isotonic exercise is suitable for joints without deformity or acute inflammation. Isometric exercise limits joint stress, maintains and restores strength, and is preferred for mechanically disrupted joints. Stretching restores ROM in the absence of acute inflammation. Patients with cervical spine involvement should avoid high-impact activities due to the risk of fracture or spinal cord injury. Resistance and aerobic training decrease inflammation, disease activity, and improve function and QOL in inflammatory myositis.45 Aquatic therapy reduces joint stress and pain, while heat provides muscle relaxation with subsequent pain reduction. Cold therapy lowers synovial collagenase, decreasing pain or muscle spasms.46 Transcutaneous electrical nerve stimulation for short periods may reduce synovial fluid and improve analgesia and strength, particularly when combined with interferential current.47 Joint protection with rest, splinting, and orthoses serves to unweigh joints, maintain alignment, mitigate deformities, and improve stability. Assistive devices or adaptive equipment decrease functional deficits.

Joint replacement surgery is indicated for patients with severe joint damage and disability or refractory pain, warranting inpatient rehabilitation of residual deficits thereafter.

Coordination of Care

Effective management of inflammatory arthritides often requires an interdisciplinary approach. Coordination between rheumatologists, physiatrists, physical and occupational therapists, social workers, and mental health specialists enhances patient care. Group or supervised individual sessions with educational and consistent support are most effective.

Patient & family education

Patient and family education targeted toward coping with pain, anticipated disease course, diet, joint protection, and disability management are cost-effective and improve work and social participation.32 Stress management training improves self-efficacy, adjustment, and health status measures.

Measurement of patient outcomes

The American College of Rheumatology (ACR) endorses functional assessment with the Patient-Reported Outcomes Measurement Information System physical function 10-item short form (PROMIS PF-10a), Health Assessment Questionnaire-II (HAQ-II), and Multidimensional HAQ (MD-HAQ).48 Disease activity and functional status can be evaluated using the Disease Activity Scale-28 (DAS28), Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI), Routine Assessment of Patient Index Data 3 (RAPID3), and the Patient Activity Scale-II (PAS-II), which count involved joints and reflect the patient’s pain and functional level.49

Translation into practice

The ACR provides clinical documentation and patient encounter forms. Multidisciplinary care and structured patient management lead to better outcomes. Education improves compliance and patient-provider communication. A rheumatologic consult is indicated to:

  • Confirm an unclear diagnosis, e.g., undiagnosed multi-system or systemic disease
  • Assess disease severity and activity
  • Manage multi-organ and extra-articular involvement
  • Treat uncontrolled disease and potentially life-threatening complications
  • Manage special circumstances, e.g., pregnancy

Cutting Edge/Emerging and Unique Concepts and Practice

New medications markedly improve outcomes. In long-standing disease, achieving low disease activity is a practical goal, while sustained drug-free remission has become a realistic goal for select patients.

Current research focuses on novel treatments with fewer adverse effects, including stem cell therapy, exosomes, or microRNA-mediated therapies targeted toward immune cells or neovascularization to decrease joint destruction.50,51 Vagus nerve-targeted neuromodulation has shown symptomatic improvement and durable clinical benefit in RA patients with intolerance or inadequate response to b/tsDMARDs.52 Biomarker identification aids with diagnosis, prognosis, and monitoring of disease progression. These tools are pivotal for stratifying treatment with the goal of improving long-term outcomes.

Gaps in Evidence-Based Knowledge

Although knowledge of the immunology, genetics, and pathophysiology of inflammatory arthritides is growing, it remains limited. There is still a lack of reliable biomarkers for early diagnosis, particularly in seronegative spondyloarthropathies. The role of advanced imaging (bone MRI, CT, etc.) in diagnostics and disease monitoring remains unclear, with conflicting evidence that requires further research. Following the COVID-19 pandemic, the use of telemedicine to diagnose and monitor patients with inflammatory arthritides has increased.53 More well-conducted studies are needed to evaluate the long-term efficacy and safety of remote care for inflammatory arthritides. While there are many new emerging pharmacologic treatments, long-term safety profiles and adverse effects will be pertinent for treatment of chronic inflammatory disorders. Additionally, despite advances in pharmacologic treatments, physiatrists continue to play a crucial role in comprehensively assessing impairments, activity limitations, and participation restrictions, as well as in coordinating effective education and rehabilitation programs to preserve the strength, mobility, and function of patients with inflammatory arthritides.

References

  1. Siegel RJ, Bridges SL, Ahmed S. HLA-C: an accomplice in rheumatic diseases. ACR Open Rheumatol. 2019;1(9):571-579.
  2. Vecellio M, Hake VX, Davidson C, Carena MC, Wordsworth BP, Selmi C. The IL-17/IL-23 axis and its genetic contribution to psoriatic arthritis. Front Immunol. 2021;11:596086.
  3. Fang WL, Zhang Q, Ma NZ, Zhang J, Ma ZQ, Sun JJ. Association between MCP-1 gene and SLE: a meta-analysis. J Eur Acad Dermatol Venereol. 2020;34(4):e198-e200.
  4. Hassan AS, Rao A, Manadan AM, Block JA. Peripheral bacterial septic arthritis: review of diagnosis and management. J Clin Rheumatol. 2017;23(8):435-442.
  5. Poudel P, Goyal A, Lappin SL. Inflammatory arthritis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023
  6. Zhang Z, Gao X, Liu S, Wang Q, Wang Y, Hou S, Wang J, Zhang Y. Global, regional, and national epidemiology of rheumatoid arthritis among people aged 20–54 years from 1990 to 2021. Sci Rep. 2025;15(1):10736.
  7. van der Woude D, van der Helm-van Mil AHM. Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2018;32(2):174-187.
  8. Margery-Muir AA, Bundell C, Nelson D, Groth DM, Wetherall JD. Gender balance in patients with systemic lupus erythematosus. Autoimmun Rev. 2017;16(3):258-268.
  9. Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545-568.
  10. Bournia VK, Fragoulis GE, Mitrou P, Tsolakidis A, Mathioudakis K, Vassilopoulos D, Tektonidou M, Paraskevis D, Sfikakis PP. Increased prevalence of inflammatory arthritis, systemic lupus erythematosus and systemic sclerosis during 2020–2023 versus 2016–2019 in a nationwide cohort study. Rheumatol Int. 2024;44(12):2837-2846.
  11. Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: NHANES 2007–2016. Arthritis Rheumatol. 2019;71(6):991-999.
  12. Swisher J, Sitton Z, Burbank K, Nelson C. Acute monoarthritis: diagnosis in adults. Am Fam Physician. 2025;111(6):497-506.
  13. Muley MM, Reid AR, Botz B, Bolcskei K, Helyes Z, McDougall JJ. Neutrophil elastase induces inflammation and pain in mouse knee joints via activation of proteinase-activated receptor-2. Br J Pharmacol. 2016;173:766-777.
  14. Gravallese EM, Firestein GS. Rheumatoid arthritis: common origins, divergent mechanisms. N Engl J Med. 2023;388(6):529-542.
  15. Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388(10055):2039-2052.
  16. Duba AS, Mathew SD. The seronegative spondyloarthropathies. Prim Care. 2018;45(2):271-287.
  17. Miller JM, Binnicker MJ, Campbell S, Carroll KC, Chapin KC, Gonzalez MD, Harrington A, Jerris RC, Kehl SC, Leal SM, Patel R, Pritt BS, Richter SS, Robinson-Dunn B, Snyder JW, Telford S, Theel ES, Thomson RB, Weinstein MP, Yao JD. Guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2024 update by IDSA and ASM. Clin Infect Dis. 2024;ciae104.
  18. Weman L, Salo H, Kuusalo L, Huhtakangas J, Kärki J, Vähäsalo P, Backström M, Sokka-Isler T. Initial presentation of early rheumatoid arthritis. PLoS One. 2023;18(7):e0287707.
  19. Cha TD, An HS. Cervical spine manifestations in patients with inflammatory arthritides. Nat Rev Rheumatol. 2013;9:423-432.
  20. Brent LH. Inflammatory arthritis: an overview for primary care physicians. Postgrad Med. 2015;121(2):148-162.
  21. Figus FA, Piga M, Azzolin I, McConnell R, Iagnocco A. Rheumatoid arthritis: extra-articular manifestations and comorbidities. Autoimmun Rev. 2021;20(4):102776.
  22. Arvikar SL, Fisher MC. Inflammatory bowel disease associated arthropathy. Curr Rev Musculoskelet Med. 2011;4:123-131.
  23. Gladman DD. Clinical, radiological, and functional assessment in psoriatic arthritis. Ann Rheum Dis. 2006;65:iii22-iii24.
  24. Kojima M, et al. Validation and reliability of the Timed Up and Go test in long-standing rheumatoid arthritis. Int J Rheum Dis. 2018;21(10):1793-1800.
  25. Sanges S, et al. Factors associated with the 6-minute walk distance in systemic sclerosis. Arthritis Res Ther. 2017;19:279.
  26. England BR, Tiong BK, Bergman MJ, et al. 2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures. Arthritis Care Res (Hoboken). 2019;71(12):1540-1555. doi:10.1002/acr.24042
  27. Payet J, Goulvestre C, Bialé L, et al. Anticyclic citrullinated peptide antibodies in rheumatoid and nonrheumatoid rheumatic disorders: experience with 1162 patients. J Rheumatol. 2014;41(12):2395-2402. doi:10.3899/jrheum.131375
  28. Weber U, Ostergaard M, Lambert RGW, Maksymowych WP. The impact of MRI on the clinical management of inflammatory arthritides. Skeletal Radiol. 2011;40:1153-1173.
  29. Hetland ML, Stengaard-Pedersen K, Junker P, Østergaard M, Ejbjerg BJ, Jacobsen S, et al. Radiographic progression and remission rates in early rheumatoid arthritis. Ann Rheum Dis. 2010;69:1789-1795.
  30. Brown AK, Conaghan PG, Karim Z, et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum. 2008;58(10):2958-2967. doi:10.1002/art.23945
  31. Ammitzbøll-Danielsen M, Fana V, Døhn UM, et al. Ultrasound assessment of hands and feet for synovitis at time of first clinical visit markedly reduces time to diagnosis in routine care. Rheumatology (Oxford). 2022;61(5):2119-2123. doi:10.1093/rheumatology/keab605
  32. Manzo A, Bugatti S, Caporali R, Montecucco C. Histopathology of synovial tissue in chronic inflammatory arthritis. Rheumatismo. 2018;70(3):121-132.
  33. Pincus T, Callahan LF. Formal education as a marker for increased mortality and morbidity in rheumatoid arthritis. J Chronic Dis. 1984;37:311-322.
  34. Combe B, Cantagrel A, Goupille P, et al. Predictive factors of 5-year HAQ disability in early rheumatoid arthritis. J Rheumatol. 2003;30(11):2344-2349.
  35. Hammod A. Rehabilitation in rheumatoid arthritis: a critical review. Musculoskelet Care. 2004;2:135-151.
  36. Findeisen KE, et al. Biological therapies for rheumatoid arthritis. Biologics. 2021;15:343-352.
  37. Gossec L, et al. EULAR recommendations for the management of psoriatic arthritis: 2023 update. Ann Rheum Dis. 2024;83(6):706-719.
  38. Hetland ML, et al. Active conventional treatment and three different biological treatments in early rheumatoid arthritis. BMJ. 2020;371:m4328.
  39. Santos Moreno P, et al. PANLAR recommendations for the management of rheumatoid arthritis. Lancet Rheumatol. 2026;8(1):e53-e65.
  40. Truong TM, Pathak GN, Singal A, Taranto V, Rao BK. Deucravacitinib for moderate to severe plaque psoriasis. Ann Pharmacother. 2024;58(4):416-427.
  41. Graf J, et al. Rosnilimab in rheumatoid arthritis: phase 2B trial [abstract]. Arthritis Rheumatol. 2025;77(Suppl 9).
  42. Verhoeven F, Tordi N, Prati C, et al. Physical activity in patients with rheumatoid arthritis. Joint Bone Spine. 2016;83:265-270.
  43. Liang H, Li WR, Zhang H, et al. Exercise and TNF inhibitor therapy in ankylosing spondylitis: meta-analysis. Medicine (Baltimore). 2015;94:e2254.
  44. Powell AP, English J. Exercise for athletes with inflammatory arthritis. Curr Sports Med Rep. 2018;17(9):302-307.
  45. Mendonça TM, Terreri MT, Silva CH, et al. Pilates in juvenile idiopathic arthritis. Arch Phys Med Rehabil. 2013;94:2093-2102.
  46. Schmidt KL. Heat, cold, and inflammation. Am J Rheumatol. 1979;38:391-404.
  47. Kavuncu V, Evcik D. Physiotherapy in rheumatoid arthritis. MedGenMed. 2004;6(2):3.
  48. Barber CEH, et al. ACR patient-reported functional status assessment measures in rheumatoid arthritis. Arthritis Care Res. 2019;71(12):1531-1539.
  49. England BR, et al. ACR disease activity measures in rheumatoid arthritis. Arthritis Care Res. 2019;71(12):1540-1555.
  50. Tang C. Pathogenesis and novel therapeutics in arthritis. Int J Mol Sci. 2019;20:1646.
  51. Ben Mrid R, et al. Anti-rheumatoid drug advancements. Biomed Pharmacother. 2022;151:113126.
  52. Tesser JRP, Crowley AR, Box EJ, et al. Vagus nerve-mediated neuroimmune modulation in rheumatoid arthritis. Nat Med. 2026;32:369-378.
  53. De Thurah A, et al. Future challenges in rheumatology: is telemedicine the solution? Ther Adv Musculoskelet Dis. 2022;14:1-10

Original Version of the Topic

Mary Catherine Spires, MD. Inflammatory Arthritides. 11/10/2011.

Previous Revision(s) of the Topic

Kemly Philip MD PhD MBE, Ajai Sambasivan MD and William Won. Inflammatory Arthritides. 7/22/2020

Loc Lam, DO, Royce Copeland, DO, Gaibo Yan, MD, Emanuel Narcis Husu, MD. Inflammatory Arthritides. 5/18/2023

Author Disclosure

Symonne Martin, MD
Nothing to Disclose

Destiny Anamege, MD, MBA
Nothing to Disclose

Emanuel Narcis Husu, MD
Nothing to Disclose